Objective To study serum peptidome profiling using Weak Cation Exchange (WCX) magnetic bead based sample fractionation method combined with matrix-assisted laser desorption ionization time of flight mass spectrometry (MALDI-TOF-MS) technology and to seek potential serum biomarkers of primary biliary cirrhosis.Methods 105 serum samples were collected from 55 patients with PBC, 25 patients with other liver disease and 25 normal controls.These serum samples were enriched by WCX magnetic bead, and the serum peptidome profiling was recognized using MALDI-TOF-MS and ClinProTools bioinformatics software was used for statistical analysis.Results 158 peptide peaks were obtained with the mass charge ratio (m/z) value ranging from 1 000 to 10 000 among the three groups.Among these peaks, 83 peptide peaks was statistically significant (P<0.001) , 31 were up-regulated and 52 down-regulated.Six peaks with m/z1062.47 Da, 5356.13 Da, 4268.63 Da, 846.18 Da, 1945.31 Da and 6649.53 Da were observed in the peptide fingerprint model.The model accuracy in blind test was 100%, 81.8% and 72.7% among PBC group, normal control group and other liver disease group, respectively.Conclusion MALDI-TOF-MS combined with ClinProTools software can be a tool to identify the biomarkers of PBC.It can be of some value to the diagnosis of PBC.
[1]闫惠平.原发性胆汁性肝硬化临床免疫特征[J].北京医学, 2010, 30 (3) :214-215.
|
[2]Oertelt S, Rieger R, Selmi C, et al.A sensitive bead assayfor antimitochondrial antibodies:Chipping away at AMA-negative primary biliary cirrhosis[J].J Hepatol, 2007, 45:659-665.
|
[3]Kita H, Imawari M, Gershwin ME.Cellular immune responsein primary biliary cirrhosis[J].Hepatol Res, 2004, 28 (1) :12-17.
|
[4]Kaplan MM, Gershwin ME.Primary biliary cirrhosis[J].NEngl J Med, 2005, 353:1261-1273.
|
[5]Heathcote EJ.Management of primary biliary cirrhosis.TheAmerican Association for the Study of Liver Diseases practiceguidelines[J].J Hepatol, 2000, 31:1005-1013.
|
[6]中华医学会传染病与寄生虫病学分会、肝病学分会.病毒性肝炎防治方案[J].中华肝脏病杂志, 2000, 8 (6) :324-329.
|
[7]Carr SA, Celis JE.Biomarkers and clinical proteomics[J].Mol Cell Proteomics, 2006, 5 (10) :17-19.
|
[8]Leung SM, Mok SC.Quality management of ovarian cancerserum profiles using functionalized magnetic beads, anchor-chip TM technology, MALDI-TOF MS and MALDI-TOF-TOF MS/MS[R].AACR Annual Meeting, 2004.
|
[9]Cheng AJ, Chen LC, Chien KY, et al.Oral cancer plasmatumor marker identified with bead-based affinity-fractiona-ted proteomic technology[J].Clin Chem, 2005, 51 (12) :2236-2244.
|
[10]Wulfkuhle JD, Liotta LA, Petricoin EF.Proteomic applicationsfor the early detection of cancer[J].Nat Rev Cancer, 2003, 3 (4) :267-275.
|
[11]李立安, 王娜, 梁婷婷, 等.血清多肽图技术建立子宫内膜异位症诊断模型[J].南方医科大学学报, 2010, 30 (4) :851-854.
|
[12]Li YZ, Hu CJ, Leng XM, et al.Promising diagnostic biomar-kers for primary biliary cirrhosis identified with magneticbeads and MALDI-TOF-MS[J].Anat Rec, 2009, 292 (3) :455-460.
|
[1] | WU Rong, LING AiMin. Primary biliary cirrhosis with autoimmune hemolytic anemia: A case report[J]. Journal of Clinical Hepatology, 2020, 36(12): 2795-2797. doi: 10.3969/j.issn.1001-5256.2020.12.030 |
[2] | Zhang XiaoXue, Feng LiNa, Chen QingLing, Kui YiWen, Yang QianQian, Wen XiaoYu, Jin QingLong. Anemia caused by primary biliary cholangitis and special reasons: A case report[J]. Journal of Clinical Hepatology, 2020, 36(4): 885-887. doi: 10.3969/j.issn.1001-5256.2020.04.038 |
[3] | Yang Xian, Tang YingMei. Health-related quality-of-life scales and related influencing factors in patients with primary biliary cholangitis[J]. Journal of Clinical Hepatology, 2020, 36(9): 2129-2132. doi: 10.3969/j.issn.1001-5256.2020.09.050 |
[4] | Chen QingLing, Kui YiWen, Zhong Rui, Yang QianQian, Zhang XiaoXue, Wen XiaoYu, Yu ChengNan, Jin QingLong. Primary biliary cholangitis with Sjogren's syndrome and immune thrombocytopenia: A case report[J]. Journal of Clinical Hepatology, 2019, 35(7): 1599-1600. doi: 10.3969/j.issn.1001-5256.2019.07.037 |
[6] | Lu FangTing, Lian ZheXiong. Application prospects of research on pathogenesis of primary biliary cirrhosis[J]. Journal of Clinical Hepatology, 2015, 31(2): 153-156. doi: 10.3969/j.issn.1001-5256.2015.02.001 |
[7] | Cao ZhangChun. Significance of combined analysis of autoantibodies in diagnosis of primary biliary cirrhosis[J]. Journal of Clinical Hepatology, 2015, 31(2): 178-180. doi: 10.3969/j.issn.1001-5256.2015.02.008 |
[8] | Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Gastroenterology, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical Association. Consensus on the diagnosis and management of primary biliary cirrhosis (cholangitis)(2015)[J]. Journal of Clinical Hepatology, 2015, 31(12): 1980-1988. doi: 10.3969/j.issn.1001-5256.2015.12.004 |
[9] | Zhu JiangYi, Han Ying. Research advances in primary biliary cirrhosis[J]. Journal of Clinical Hepatology, 2015, 31(2): 163-164. doi: 10.3969/j.issn.1001-5256.2015.02.004 |
[10] | Wang YiPeng, Sun LiMei, Liu YanMin, Zhang Xin, Zhang HaiPing, Zhao DanTong, Yan HuiPing. Analysis of serological characteristics in viral hepatitis patients with positive AMA-M2[J]. Journal of Clinical Hepatology, 2015, 31(8): 1278-1282. doi: 10.3969/j.issn.1001-5256.2015.08.023 |
[11] | Shi GuangYing, Ma XiaoYuan, Xie JingDong. Changes in T lymphocyte subsets and cytokines in peripheral blood of patients with primary biliary cirrhosis after treatment with different doses of ursodeoxycholic acid[J]. Journal of Clinical Hepatology, 2015, 31(9): 1447-1451. doi: 10.3969/j.issn.1001-5256.2015.09.020 |
[12] | Yu Yuan, Yang ZongGuo, Chen ChiChi, Lu YunFei, Xu QingNian, Chen XiaoRong. Efficacy of adjuvant therapy with fenofibrate for primary biliary cirrhosis: a Meta-analysis[J]. Journal of Clinical Hepatology, 2015, 31(10): 1630-1633. doi: 10.3969/j.issn.1001-5256.2015.10.017 |
[13] | Li Bing, Shao Qing, Niu XiaoXia, Zhang Jian, Chen GuoFeng. Clinical features and diagnosis of autoimmune hepatitis-primary biliary cirrhosis overlap syndrome[J]. Journal of Clinical Hepatology, 2014, 30(5): 413-416. doi: 10.3969/j.issn.1001-5256.2014.05.007 |
[14] | Li YuanYuan, Wang LiFeng, Geng Hua, Yu ShuangJie, Lin Hu, Lu: Sa, Chen LiMing, Zhang Zheng, Wang FuSheng. Changes in frequencies of peripheral blood lymphocyte subsets and their clinical significance in patients with autoimmune liver diseases[J]. Journal of Clinical Hepatology, 2014, 30(5): 409-412. doi: 10.3969/j.issn.1001-5256.2014.05.006 |
[15] | Li YinPing, Niu JunQi. Significance of serum anti-gp210 antibody detection in diagnosis of primary biliary cirrhosis[J]. Journal of Clinical Hepatology, 2014, 30(5): 466-468. doi: 10.3969/j.issn.1001-5256.2014.05.023 |
[16] | Lu WeiTing, Jiang XingHuo, Guo HaiYan, Zhao JianXue. Clinical features of primary biliary cirrhosis: a clinical analysis of 70 cases[J]. Journal of Clinical Hepatology, 2013, 29(12): 926-928. doi: 10.3969/j.issn.1001-5256.2013.12.013 |
[17] | Zhao DanTong, Yan HuiPing, Liao HuiYu, Liu YanMin, Feng Xia, Zhao Yan, Liu XiuHong, Kong XiangSha. Expression of Toll like receptors on peripheral blood mononuclear cells and their influence on CD4+CD25+T regula- tory cells in patients with primary biliary cirrhosis[J]. Journal of Clinical Hepatology, 2012, 28(1): 58-62. |
[18] | Liu MeiLing. Clinical analysis of primary biliary cirrhosis combined with diabetes mellitus[J]. Journal of Clinical Hepatology, 2011, 27(6): 635-637. |
[19] | Zhang YanChao, Chen Ming, Chen Dan. Clinical significance of antibody profiling in autoimmune liver disease [J]. Journal of Clinical Hepatology, 2010, 26(3): 319-320. |
[20] | Fan Xue, Jia JiDong. Diagnosis and treatment of primary biliary cirrhosis in Pacific Asia region[J]. Journal of Clinical Hepatology, 2010, 26(4): 365-367. |